Intelligence / Healthtech / New Clinical Trials / Avata Biosciences Holdings Ltd
Avata Biosciences Holdings Ltd
5 Nov 2026: Trial registered · A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Cannabidiol Capsules (AVAT-121) and Epidyolex® in Healthy Adults. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 5 Nov 2026
- Title
- A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Cannabidiol Capsules (AVAT-121) and Epidyolex® in Healthy Adults
- Conditions
- Focal Onset Seizure
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07918469
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Avata Biosciences Holdings Ltd
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.